3 ASX health care shares that outpaced the market on Friday

These three healthcare shares had a better day than the broader index.

The benchmark S&P/ASX 200 Index (ASX: XJO) finished up 0.17% at 7,392 points after spending most of the week in the red.

Even with the gain, three ASX health care shares stood out today, with each posting returns that outpaced the market.

Here is the rundown on what happened with each today.

three excited doctors with hands in the air

Image source: Getty Images

Trajan Group Holdings Ltd (ASX: TRJ)

Shares in global analytical science and device company Trajan Group jumped over 8% today and finished near an all-time high.

Investors bought into the company's shares after it announced it had completed the acquisition of German company Axel Semrau overnight.

The company completed the deal on a consideration of 17 million euros. This gives the company further exposure to the European markets.

The Axel Semrau company manufactures laboratory automation and chromatography software and detection systems. The company reported FY21 (year ended Sept 2021) revenues of 14.9 million euros and EBITDA of 1.46 million euros.

Trajan shares traded as high as 8% late in the session today, after climbing gradually from the open.

Early investors have been rewarded with their holdings in Trajan Group. Its share price has gained over 105% since listing in early July.

SDI Limited (ASX: SDI)

Shares in supplier of dental restoration materials SDI traded as much as 7% higher before dumping just before the closing bell today.

At market close, SDI's shares are fetching $1.07 apiece and are up only 1.90%. They were on the move as Investors responded positively to the company's AGM release today.

In its address, the company's chairman Jeffery Cheetham gave an overview of the company's operations for the year. He also addressed how the firm has created value for its shareholders in that time.

For instance, SDI declared a final dividend of 1.65 cents per share on top of its interim dividend of 1.5 cents per share. Combined, this signified a 70.3% growth in the dividend payout ratio from the previous year.

SDI also launched several new products in its whitening and glass ionomer range and continues to invest in research development, as per its report.

The SDI share price has gained over 31% in the past 12 months after rallying another 36% this year to date.

Bcal Diagnostics Ltd (ASX: BDX)

Shares in Bcal Diagnostics hit an intraday high of 15.2 cents in early trade today and held course until the finish.

The gains are a welcomed turn for Bcal shareholders, who have lost 39% in the past few months since the company listed.

There wasn't any price-sensitive news out of Bcal's camp today, however, its share price has been on the downward slope for the last few weeks.

But, the company did release trial results for its BCAL test early in the month. That data readout supported and reinforced previous studies conducted by the company.

Bcal advised its BCAL test showed positive results in samples obtained from a recent Cohort 4 test. The company is now seeking to further refine its BCAL algorithm and biomarker development.

Investors have bought in at the lows today and volume is about 50% of the company's 4-week average volume for number of shares traded.

ASX health care shares have done well across the board today as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) finished up around 1%, after gaining more than 6% in the past month, indicating strengths across the broad sector.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended SDI Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »